Direkt zum Inhalt
Merck

An update on the use of ophthalmic ketorolac tromethamine 0.4%.

Expert opinion on pharmacotherapy (2005-12-24)
Henry D Perry, Eric D Donnenfeld
ZUSAMMENFASSUNG

Ketorolac tromethamine 0.4% ophthalmic solution, a recent reformulation of the original ketorolac tromethamine 0.5% solution, is indicated for the reduction of ocular pain and burning/stinging following cataract and refractive surgery. Studies have demonstrated that ketorolac tromethamine 0.4% has equivalent efficacy to ketorolac tromethamine 0.5% in reducing postsurgical inflammation and controlling pain. Several studies have demonstrated that, as well as reducing pain and ocular inflammation, ketorolac tromethamine 0.4% effectively treats cystoid macular oedema, inhibits miosis and may prevent cystoid macular oedema when used both pre- and postoperatively. Ketorolac tromethamine 0.4% is a versatile agent and is effective when used as either monotherapy or as an adjunct therapy to steroids.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Supelco
Ketorolac-Tromethamin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Ketorolac Tris-salz, ≥99%, crystalline
Ketorolac-Trometamol, European Pharmacopoeia (EP) Reference Standard
Ketorolac-Trometamol für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard